Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

TY - JOUR

T1 - Marginal zone lymphomas

T2 - ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

AU - ESMO Guidelines Committee

AU - Zucca, E.

AU - Arcaini, L.

AU - Buske, C.

AU - Johnson, P. W.

AU - Ponzoni, M.

AU - Raderer, M.

AU - Ricardi, U.

AU - Salar, A.

AU - Stamatopoulos, K.

AU - Thieblemont, C.

AU - Wotherspoon, A.

AU - Ladetto, M.

N1 - Funding Information: The ESMO Guidelines Committee would like to thank the ESMO Faculty and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. EZ has received research support from Roche, Janssen and Celgene; LA has reported consultancy or advisory role for Roche, Bayer, Celgene, Sandoz and Gilead Sciences, has received research funding from Gilead Sciences and travel expenses from Roche, Celgene, Gilead Sciences and EUSA Pharma and is a member of the speaker's bureau for Celgene; CB has received research support from Roche, Bayer, Amgen and Janssen; PWJ has received research support from Epizyme and Janssen and consultancy for Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer, Celgene, Carrick, Karus, Genmab and Incyte; MR has received support from Celgene, Novartis, Ipsen and Roche; UR is a member of the speaker's bureau of AstraZeneca, Merck, Sharp and Dohme and Bayer; AS is a member of the speaker's bureau of Janssen, Roche and Mundipharma; KS has reported consultancy and advisory board for Janssen and Gilead Sciences and has received institutional research support from Janssen, Gilead Sciences and AbbVie; CT has reported consultancy or advisory role for Janssen, Roche, Bayer and Celgene, has received research funding from Roche and Janssen and travel expenses from Sanofi and Roche and is a member of the speaker's bureau for Cellectis; AW has received service fees from Celgene and Bristol-Myers Squibb and travel expenses from Pfizer; ML is a member of the speaker's bureau of Celgene, Janssen-Cilag, Roche, Bayer, Amgen and Mundipharma; MP has declared no conflicts of interest. Funding Information: EZ has received research support from Roche , Janssen and Celgene; LA has reported consultancy or advisory role for Roche , Bayer , Celgene , Sandoz and Gilead Sciences , has received research funding from Gilead Sciences and travel expenses from Roche , Celgene , Gilead Sciences and EUSA Pharma and is a member of the speaker’s bureau for Celgene; CB has received research support from Roche , Bayer , Amgen and Janssen; PWJ has received research support from Epizyme and Janssen and consultancy for Boehringer Ingelheim , Bristol-Myers Squibb , Pfizer , Celgene , Carrick, Karus, Genmab and Incyte; MR has received support from Celgene , Novartis , Ipsen and Roche; UR is a member of the speaker’s bureau of AstraZeneca , Merck, Sharp and Dohme and Bayer; AS is a member of the speaker’s bureau of Janssen, Roche and Mundipharma; KS has reported consultancy and advisory board for Janssen and Gilead Sciences and has received institutional research support from Janssen, Gilead Sciences and AbbVie; CT has reported consultancy or advisory role for Janssen, Roche , Bayer and Celgene , has received research funding from Roche and Janssen and travel expenses from Sanofi and Roche and is a member of the speaker’s bureau for Cellectis; AW has received service fees from Celgene and Bristol-Myers Squibb and travel expenses from Pfizer; ML is a member of the speaker’s bureau of Celgene , Janssen-Cilag, Roche , Bayer , Amgen and Mundipharma; MP has declared no conflicts of interest.

PY - 2020/1

Y1 - 2020/1

KW - clinical practice guidelines

KW - extranodal marginal zone lymphoma (EMZL)

KW - marginal zone B-cell lymphoma (MZL)

KW - mucosa-associated lymphoid tissue (MALT)

KW - nodal marginal zone lymphoma (NMZL)

KW - splenic marginal zone lymphoma (SMZL)

UR - https://www.scopus.com/pages/publications/85077682297

U2 - 10.1016/j.annonc.2019.10.010

DO - 10.1016/j.annonc.2019.10.010

M3 - Article

SN - 0923-7534

VL - 31

SP - 17

EP - 29

JO - Annals of Oncology

JF - Annals of Oncology

IS - 1

ER -